Orbis and Allan Gray report 4.24M Genmab (GMAB) shares held
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd report a combined 6.6% beneficial stake in Genmab A/S common stock on a Schedule 13G/A. They disclose beneficial ownership of 4,237,472 shares, with Orbis holding 4,229,662 shares and Allan Gray holding 7,810 shares.
Each firm has sole voting and dispositive power over its respective holdings and reports no shared power. They classify themselves as non-U.S. institutions equivalent to investment advisers and state the securities are held in the ordinary course of business, not to change or influence control of Genmab A/S.
Positive
- None.
Negative
- None.
FAQ
What percentage of Genmab A/S (GMAB) does Orbis and Allan Gray report owning?
Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd together report beneficial ownership of 6.6% of Genmab A/S common stock. This corresponds to a combined holding of 4,237,472 shares as of the event date stated in the Schedule 13G/A filing.
Do Orbis and Allan Gray intend to influence control of Genmab A/S (GMAB)?
They state the Genmab A/S securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing specifies they are not participating in any control-related transaction regarding the issuer.
Are Orbis Investment Management Ltd and Allan Gray Australia considered a group in this Genmab A/S filing?
The filing notes Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd are making the Schedule 13G/A together but explicitly states that no reporting person represents it is a member of a group for Section 13(d)(3) purposes and each disclaims beneficial ownership of the other's shares.
What type of institutions are Orbis and Allan Gray in relation to Genmab A/S (GMAB)?
Both Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd are classified as non-U.S. institutions equivalent to investment advisers. The certification states their foreign regulatory schemes are substantially comparable to those applicable to functionally equivalent U.S. institutions.